CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, November 6th, to ...

Apyx Medical (NasdaqGS:APYX) Conference Call Summary Company Overview - **Company**: Apyx Medical Corporation - **Event Date**: October 14, 2025 - **Key Product**: Apyx One Console, a body contouring system Industry Insights - **Market Context**: The surgical aesthetics market is evolving, particularly due to the rise of GLP-1 therapies for weight loss, leading to increased demand for body contouring solutions among post-weight loss patients [4][6] - **Market Size**: GLP-1 therapies are projected to exceed $100 billion by 2030, with 44% of users spending between $2,000 and $5,000 on aesthetic procedures, a 25% increase in spending [6] - **Patient Demographics**: 63% of GLP-1 users are new to aesthetics post-weight loss, indicating a growing patient population for plastic surgeons [6] Product Launch and Performance - **Product Launch**: Apyx One Console received approval in May 2025 and has undergone a successful soft launch with key surgeons across the U.S. [5][4] - **Sales Update**: Commercial sales began in September 2025, with ongoing sales in Q4 2025. A 510(k) submission for the power-assisted handpiece is expected to receive clearance in Q1 2026 [5][6] - **Technological Advancements**: The Apyx One Console integrates multiple technologies, including ultrasound-assisted liposuction and Renuvion for skin tightening, designed based on feedback from leading plastic surgeons [10][12] Clinical Insights - **Surgical Trends**: There has been a decline in liposuction procedures by 10.7%, while surgical lifts have increased by over 20%, reflecting the need for more complex surgical interventions for patients with lax skin [7][8] - **Patient Concerns**: 72% of GLP-1 users report loose skin as their primary concern, with 57% seeking treatment within six months post-weight loss [9] Feedback and Reception - **Surgeon Feedback**: Surgeons have expressed high satisfaction with the Apyx One Console, describing it as revolutionary and comparing it to luxury vehicles like Ferraris and Lamborghinis [13][14] - **Clinical Efficiency**: The integration of technologies in the Apyx One Console has led to improved surgical efficiency, with reduced procedure times and enhanced patient outcomes [32][51] Future Outlook - **Market Positioning**: Apyx Medical is well-positioned to capture growth in the surgical aesthetics market, particularly among post-weight loss patients seeking body contouring solutions [6][4] - **Anticipated Developments**: The upcoming launch of the power-assisted handpiece is expected to further enhance the capabilities of the Apyx One Console, attracting more surgeons and patients [65][66] Additional Insights - **Patient Experience**: The Apyx One Console aims to simplify the surgical process, reducing the need for multiple devices and improving the overall patient experience [21][22] - **Technological Trust**: Surgeons have shown a willingness to adopt the Apyx One Console based on the company's commitment to evidence-based medicine and the collaborative development process involving top surgeons [66][68] This summary encapsulates the key points discussed during the Apyx Medical conference call, highlighting the company's strategic positioning, product innovations, and the evolving landscape of the surgical aesthetics market.

Core Insights - Apyx Medical Corporation has initiated the nationwide commercial launch of the AYON Body Contouring System, with a focus on expanding its capabilities to include power liposuction through a new 510(k) premarket notification to the FDA [2][3] - The AYON system is designed to integrate various body contouring procedures into a single platform, enhancing workflow for surgeons and potentially improving patient outcomes [3][5] - Apyx Medical is hosting a virtual event on October 14, 2025, featuring key opinion leaders to discuss the commercial launch and advancements of the AYON system [4] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly in the cosmetic surgery market with products like Renuvion and the AYON Body Contouring System [5] - The AYON Body Contouring System is FDA-cleared and combines multiple functionalities, including fat removal and tissue contraction, aimed at providing comprehensive body contouring treatments [5] - The company has received positive feedback from early adopters of the AYON system, indicating strong market interest and potential for growth [3]

Core Insights - Apyx Medical Corporation announced a virtual key opinion leader event to discuss the commercial launch of its new AYON Body Contouring System on October 14, 2025 [1] - The AYON Body Contouring System is the first FDA cleared all-in-one platform for aesthetic surgical suites, integrating multiple capabilities for improved surgical outcomes [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and AYON in the cosmetic surgery market [5] - The company’s Renuvion and J-Plasma technologies provide controlled heat to tissue, supported by over 90 clinical publications [5] Key Opinion Leader Event - The event will feature Dr. Paul Vanek, a renowned plastic surgeon, who will discuss the AYON Body Contouring System alongside company management [1][2] - A live Q&A session will follow the formal presentations, allowing for direct engagement with attendees [3] Product Features - The AYON Body Contouring System combines precision, versatility, and innovation, designed to streamline procedures and maximize patient outcomes [2] - It integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, setting a new standard in surgical care [2] Leadership Profile - Dr. Paul Vanek is recognized for his extensive experience in the field, having built a successful practice and contributed to various medical innovations [4] - He has held leadership roles in hospital systems and has been involved in numerous philanthropic efforts [4]

Summary of Apex Medical Conference Call Company Overview - **Company**: Apex Medical - **Industry**: Medical Technology, specifically in surgical aesthetics - **Specialization**: Helium plasma energy solutions for minimally invasive cosmetic and surgical procedures [2][3] Core Insights and Arguments - **Market Leadership**: Apex Medical is positioned as a leader in surgical technologies for minimally invasive aesthetic procedures, particularly with their FDA-approved device, Renuvion, for treating loose and lax skin [4][5] - **Impact of GLP-1 Drugs**: The aesthetic market has significantly changed due to the introduction of GLP-1 drugs, which are projected to become a $100 billion market by 2030. Nearly 63% of GLP-1 users are new to aesthetic treatments, indicating a growing customer base for aesthetic procedures [5][6] - **Procedure Trends**: There has been a decline in liposuction procedures (down 10%), while surgical lifts have increased by over 20%. This trend aligns with the need for surgical interventions as patients lose weight and experience skin laxity [6][7] - **Patient Behavior**: 57% of patients seek treatment within six months after reaching their ideal weight, indicating a strong demand for surgical interventions post-weight loss [8][9] Financial Performance and Market Potential - **Revenue**: Apex Medical generated approximately $50 million in revenue last year, operating in a market valued at around $10 billion [11] - **Single-Use Handpieces**: The company sold 93,000 single-use handpieces, with an average selling price (ASP) of $500, marking a 14% growth in this segment [12] - **Cost Management**: The company aims to reduce operating costs to below $40 million this year, down from $53 million in 2023, to achieve profitability [25][26] Product Development and Launch - **AON Body Contouring System**: The AON system, approved in May, is set to launch commercially in September. It consolidates multiple technologies into one platform, enhancing efficiency and safety in surgical procedures [18][19] - **Ultrasonic Technology**: The AON system features advanced ultrasonic technology (LIFT technology) that improves fat emulsification speed and safety compared to existing technologies [20][21] Marketing and Consumer Engagement - **Direct-to-Consumer (DTC) Strategy**: Apex Medical is enhancing its DTC marketing for Renuvion to educate consumers about skin laxity treatment options, while focusing on B2B strategies for AON [22] - **Awards and Recognition**: Renuvion recently won the Best Minimally Invasive Skin Tightener award, highlighting its significance in the beauty market [22] Global Presence and Future Plans - **International Operations**: The company has R&D and manufacturing facilities in the U.S. and Bulgaria, with a joint venture in China, where it has recently begun commercial operations [23][24] - **Future Focus**: Apex Medical plans to expand the adoption of Renuvion and continue developing AON for international markets, emphasizing evidence-based medicine and clinical research [27][28] Additional Insights - **Surgeon Partnerships**: The company focuses on building partnerships with plastic surgeons, aiming to support their practices and improve patient outcomes [30][31] - **Market Trends**: The rise of GLP-1 drugs is expected to influence aesthetic treatment trends globally, with increasing accessibility in markets like Brazil [33]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 decreased by 6% to $11,400,000 compared to $12,100,000 in the same period last year, primarily driven by a decrease in OEM product sales [6][18] - Gross profit for Q2 2025 decreased to $7,100,000 from $7,500,000 in the prior year, while gross profit margin slightly increased to 62.3% from 61.7% [20] - Net loss attributable to stockholders was $3,800,000 or $0.09 per share for Q2 2025, compared to $6,600,000 or $0.19 per share in the prior year [22] Business Line Data and Key Metrics Changes - Revenue for the Advanced Energy segment was relatively flat at $9,700,000 compared to $9,800,000 last year, reflecting a decrease in the volume of single-use handpieces sold domestically [18][19] - OEM segment sales decreased by 29% or approximately $1,700,000 compared to the previous year, with domestic revenue down 11% to $7,800,000 and international revenue down 4% to $3,600,000 [19] Market Data and Key Metrics Changes - The global aesthetic market remains challenging, but the company is identifying key growth opportunities, particularly with the Renuvion product [9][10] - The company has launched Renuvion in China, which is expected to be a significant growth driver due to the emerging middle to upper class and the presence of approximately 5,000 plastic surgeons in the region [12][40] Company Strategy and Development Direction - The company is focused on returning to growth and has appointed two senior sales leaders to enhance its market presence in North America and Europe/Asia [5] - The launch of the Aon system is a key strategic priority, with expectations of significant sales momentum as it addresses current market needs for body contouring [13][16] - The company aims to expand Renuvion's footprint in international markets, with a strong marketing campaign that has exceeded expectations in 2025 [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong early results from Aon presales and a belief that the next decade will be a significant growth period for surgeons [29][30] - The company anticipates a different seasonal revenue pattern due to the timing of Aon product shipments, which could lead to a stronger Q3 and Q4 [20][35] Other Important Information - Cash used in operating activities decreased to $1,200,000 compared to $4,300,000 in the prior year, indicating improved cash and working capital management [22] - The company updated its 2025 revenue guidance to a range of $50,000,000 to $52,000,000, up from previous guidance, reflecting confidence in the Aon launch [23][24] Q&A Session Summary Question: Customer receptivity to Aon and capital purchases in the current market - Management reported that the reaction from doctors to Aon has been overwhelmingly positive, indicating a strong demand for innovation in the market [26][28] Question: Impact of new commercial hires on product launches - The new hires bring extensive experience in the aesthetic space, which is expected to drive the adoption of Aon and Renuvion [31][33] Question: Seasonal revenue patterns and expectations for Q3 and Q4 - Management clarified that while a typical dip from Q2 to Q3 is expected, the launch of Aon could lead to a stronger Q3, with significant shipments anticipated in Q4 [34][35] Question: Market opportunity in China and partnership with GlamMoon - The company sees a substantial opportunity in China, supported by a strong partnership with GlamMoon, which has extensive facilities in the region [40][42]

Core Points - Apyx Medical Corporation granted a nonstatutory stock option to John Featherstone, Vice President of North American Sales, for 100,000 shares as an inducement for employment [1][2] - The stock option has an exercise price of $1.85, which is the closing price of Apyx Medical's common stock on the grant date [2] - The stock option vests over a four-year period, with 25% vesting on the first anniversary and the remainder vesting annually, contingent on continued employment [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Insights - Apyx Medical Corporation has launched Renuvion in China, marking a significant step in its global expansion strategy [2][3] - The company has entered into a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd., to facilitate the sales and marketing of Renuvion in the Chinese market [1][2] - Initial market clearance has been received from the National Medical Products Administration of China, indicating regulatory approval for the product [1] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion and J-Plasma, which provide controlled heat to tissue for surgical applications [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents, showcasing the company's commitment to clinical validation [3] Partner Overview - BeauCare Clinics Investment Co., Ltd. (BCC) is a leading player in China's medical aesthetics industry, operating over 60 medical aesthetics hospitals and clinics across 15 cities [4] - BCC has established a strong supply chain and a group purchasing alliance with over 400 members, enhancing its market position in the medical aesthetics sector [4]

Core Viewpoint - Apyx Medical Corporation will release its financial results for Q2 of fiscal year 2025 on August 7, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 4:30 p.m. Eastern Time on the same day [2] - Interested parties can join the call by dialing 800-717-1738 or 646-307-1865 for international callers, using access code 35370 [2] - A live webcast of the call will be available on the company's website and will be archived for future reference [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and the AYON Body Contouring System™ [3] - The company’s Helium Plasma Platform Technology is utilized in both cosmetic surgery and hospital surgical markets, providing surgeons with controlled heat to achieve desired results [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical publications, showcasing the company's commitment to clinical validation [3] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Viewpoint - Apyx Medical Corporation has received FDA 510(k) clearance for the AYON Body Contouring System, marking a significant advancement in aesthetic surgical technology and is set to launch commercially in the second half of 2025 [1][6]. Group 1: Product Overview - The AYON Body Contouring System is an all-in-one platform designed for body contouring, integrating fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities [3][4]. - It features LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, aiming to improve surgical precision and patient outcomes [3][6]. - The system is expected to revolutionize body contouring procedures and is backed by Apyx Medical's expertise and evidence-based design [3][6]. Group 2: Market Context - The aesthetics market is projected to see a rapid increase in body contouring procedures, particularly as over 15 million patients using GLP-1 drugs experience significant weight loss and seek solutions for loose skin [6]. - The initial FDA clearance for AYON covers various aesthetic treatments, including ultrasound-assisted liposuction and electrocoagulation for tissue removal, with plans for further indications like power liposuction [4][5]. Group 3: Company Background - Apyx Medical Corporation specializes in advanced energy technology, particularly its Helium Plasma Platform Technology products marketed as Renuvion and the AYON Body Contouring System [7]. - The effectiveness of Renuvion and J-Plasma technologies is supported by over 90 clinical documents, showcasing the company's commitment to innovation in surgical solutions [7].